Calliditas Therapeutics
planned open label extension and chronic dosing trials | Calliditas Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
June 2020
Slide
20 of 38
Related slides by other companies
argenx SE
Investor Presentation
March 2023
chronic inflammatory polyneuropathy adhere trial | argenx SE
argenx SE
Investor Presentation
April 2023
chronic inflammatory polyneuropathy adhere trial committee grip strength weekly sun followed by | argenx SE
argenx SE
Investor Presentation
February 2023
chronic inflammatory polyneuropathy adhere trial | argenx SE
argenx SE
Investor Presentation
June 2023
chronic inflammatory polyneuropathy adhere trial | argenx SE
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights